Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Akt
    (1)
  • Apoptosis
    (1)
  • CDK
    (1)
  • ERK
    (1)
  • PKA
    (1)
  • PKC
    (1)
  • PROTACs
    (1)
  • Others
    (5)
Filter
Search Result
Results for "

fb-23-2

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    7
    TargetMol | Activity
  • PROTAC Products
    1
    TargetMol | inventory
A-674563 2HCl(552325-73-2(fb-2hcl))
T6139L
A-674563 2HCl is an Akt1 inhibitor with Ki of 11 nM, modest potent to PKA and >30-fold selective for Akt1 over PKC.
  • $78
In Stock
Size
QTY
FB23-2
T71382243736-45-8
FB23-2 is a potent and selective inhibitor of the mRNA N6-methyladenosine (m6A) demethylase FTO with an IC50 of 2.6 μM.
  • $32
In Stock
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2-IN-23 disodium
T74944L
SARS-CoV-2-IN-23 disodium, a medium-length molecular tweezer and two-armed diphosphate ester, demonstrates antiviral properties by inhibiting SARS-CoV-2 activity and spike pseudoparticle transduction with IC50 values of 8.2 μM and 2.6 μM, respectively. Additionally, it disrupts liposomal membranes with an EC50 of 4.4 μM [1].
  • Inquiry Price
Size
QTY
ML 2-23
T79081
ML 2-23 is a potent BCR-ABL degrader functioning as a PROTAC, demonstrating selective proteasome-dependent degradation of BCR-ABL in leukemia cells [1].
  • Inquiry Price
Size
QTY
COX-2-IN-23
T633482417995-08-3
COX-2-IN-23 is a selective inhibitor of COX-2, with IC50 values of 0.28 and 20.14 μM for COX-2 and COX-1, respectively.COX-2-IN-23 exhibits anti-inflammatory effects as well as low ulcerogenic effects.
  • $1,520
6-8 weeks
Size
QTY
SARS-CoV-2-IN-23
T60841
SARS-CoV-2-IN-23 (compound GRL-0617) is an inhibitor of SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 2.3 μM [1].
  • $1,520
10-14 weeks
Size
QTY
VEGFR-2-IN-23
T616312411174-53-1
VEGFR-2-IN-23 (compound 11b) is a highly potent and selective inhibitor of VEGFR-2, with an IC50 value of 0.34 nM. It demonstrates significant antitumor activity by inducing apoptosis and causing cell cycle arrest at the G1 phase [1].
  • $1,520
6-8 weeks
Size
QTY